The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes

Overview

Journal J Transl Int Med

Publisher Sciendo

Specialty General Medicine

Date 2017 Nov 1

PMID 29085786

Citations 31

Authors

Ming Hong

Guangsheng He

Affiliations

Soon will be listed here.

Citing Articles

Redox biomarker levels in patients with myelodysplastic syndrome.

Tsiara E, Makri S, Skaperda Z, Giannakoulas N, Vasilopoulos G, Kouretas D Biomed Rep. 2025; 22(3):45.

PMID: 39882334 PMC: 11775644. DOI: 10.3892/br.2025.1923.

An uncommon triad of myelodysplastic syndrome, Crohn's disease and autoimmune hepatitis: A case report and review of the literature.

Cheffai A, Boufrikha W, Rakez R, Ben Ghechir A, Laatiri M Leuk Res Rep. 2024; 22:100487.

PMID: 39628604 PMC: 11612820. DOI: 10.1016/j.lrr.2024.100487.

Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.

Fahim S, Tice J, Luu L, Carlson J, Richardson M, Herce-Hagiwara B J Manag Care Spec Pharm. 2024; 30(12):1479-1485.

PMID: 39612256 PMC: 11607211. DOI: 10.18553/jmcp.2024.30.12.1479.

Cytogenetic profile and risk of transformation to acute myeloid leukemia (AML) in Indonesian patients with myelodysplastic syndrome (MDS): a pilot study.

Sutandyo N, Kosasih A, Sari R, Setiawan L, Rinaldi I, Maskito V F1000Res. 2024; 13:167.

PMID: 39600341 PMC: 11589415. DOI: 10.12688/f1000research.143170.1.

Peculiar -mer Spectra Are Correlated with 3D Contact Frequencies and Breakpoint Regions in the Human Genome.

Hikmat W, Sievers A, Hausmann M, Hildenbrand G Genes (Basel). 2024; 15(10).

PMID: 39457371 PMC: 11506876. DOI: 10.3390/genes15101247.

References

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G . Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-506. PMC: 3159042. DOI: 10.1056/NEJMoa1013343. View

Bejar R, Stevenson K, Caughey B, Lindsley R, Mar B, Stojanov P . Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014; 32(25):2691-8. PMC: 4207878. DOI: 10.1200/JCO.2013.52.3381. View

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

Patnaik M, Hanson C, Sulai N, Hodnefield J, Knudson R, Ketterling R . Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood. 2012; 119(24):5674-7. DOI: 10.1182/blood-2012-03-415356. View

Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-51. DOI: 10.1182/blood-2009-03-209262. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G . TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011; 29(15):1971-9. DOI: 10.1200/JCO.2010.31.8576. View

Cargo C, Rowbotham N, Evans P, Barrans S, Bowen D, Crouch S . Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015; 126(21):2362-5. DOI: 10.1182/blood-2015-08-663237. View

Mallo M, Del Rey M, Ibanez M, Calasanz M, Arenillas L, Larrayoz M . Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013; 162(1):74-86. DOI: 10.1111/bjh.12354. View

10.

Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J . TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014; 124(17):2705-12. PMC: 4208285. DOI: 10.1182/blood-2014-06-582809. View

11.

Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G . Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2013; 28(2):241-7. PMC: 3918868. DOI: 10.1038/leu.2013.336. View

12.

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

13.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

14.

Kwok B, Hall J, Witte J, Xu Y, Reddy P, Lin K . MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015; 126(21):2355-61. PMC: 4653764. DOI: 10.1182/blood-2015-08-667063. View

15.

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P, Mar B . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-98. PMC: 4306669. DOI: 10.1056/NEJMoa1408617. View

16.

Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jadersten M, Jansson M . SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015; 126(2):233-41. PMC: 4528082. DOI: 10.1182/blood-2015-03-633537. View

17.

Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti G, Kulasekararaj A . p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014; 99(6):1041-9. PMC: 4040908. DOI: 10.3324/haematol.2013.098103. View

18.

Bejar R . Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014; 99(6):956-64. PMC: 4040892. DOI: 10.3324/haematol.2013.085217. View